Objective. IgG anti-DWEYS antibodies cross-reactive with DNA and the N-methyl-D-aspartate receptor subunits GluN2A and GluN2B are known to be associated with neuropsychiatric systemic lupus erythematosus (NPSLE). IgG anti-DWEYS have not been investigated in demyelinating NPSLE or in another demyelinating disorder, neuromyelitis optica spectrum disorder (NMOSD), which is a disease also found mainly in young women and associated with aquaporin 4 (AQP-4) or myelin oligodendrocyte glycoprotein (MOG) antibodies. This study was undertaken to investigate the frequency of all of these brain-reactive antibodies in patients with NPSLE, those with demyelinating NPSLE, and those with NMOSD.
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Objective. IgG anti-DWEYS antibodies cross-reactive with DNA and the N-methyl-D-aspartate receptor subunits GluN2A and GluN2B are known to be associated with neuropsychiatric systemic lupus erythematosus (NPSLE). IgG anti-DWEYS have not been investigated in demyelinating NPSLE or in another demyelinating disorder, neuromyelitis optica spectrum disorder (NMOSD), which is a disease also found mainly in young women and associated with aquaporin 4 (AQP-4) or myelin oligodendrocyte glycoprotein (MOG) antibodies. This study was undertaken to investigate the frequency of all of these brain-reactive antibodies in patients with NPSLE, those with demyelinating NPSLE, and those with NMOSD.
Methods. Serum samples from patients with NPSLE (n = 108), patients with SLE without neuropsychiatric manifestations (n = 38), patients with NMOSD (n = 33), and healthy controls (n = 106) were assessed for the frequency of IgG anti-brain antibodies as well as IgG antibodies to AQP-4, MOG, GluN2A/GluN2B, and double-stranded DNA (dsDNA).
Results. Sera were positive for IgG anti-AQP-4 antibodies in 27 (82%) of 33 patients with NMOSD and 3 (27%) of 11 patients with demyelinating NPSLE, whereas all sera from patients with non-demyelinating NPSLE, patients with SLE, and healthy controls were negative for IgG anti-AQP-4. IgG anti-MOG were detected at high titers in 3 (50%) of 6 patients with NMOSD who were negative for IgG anti-AQP-4, and at low titers in 2 (18%) of 11 patients with demyelinating NPSLE and 1 (1%) of 97 patients with non-demyelinating NPSLE. IgG antibodies to dsDNA were present in 11 (33%) of 33 patients with NMOSD. Only 4 (12%) of 33 patients with NMOSD were positive for IgG anti-DWEYS, compared to 11 (29%) of 38 patients with SLE and 59 (55%) of 108 patients with NPSLE. IgG anti-DWEYS antibodies were present in 56 (58%) of 97 patients with non-demyelinating NPSLE and 3 (27%) of 11 patients with demyelinating NPSLE. Serum IgG brain-reactive antibodies were present at a similar frequency in patients with non-demyelinating NPSLE (72 [75%] of 96), those with demyelinating NPSLE (9 [82%] of 11), and those with SLE (32 [84%] of 38), but were less frequent in patients with NMOSD (20 [61%] 
of 33).
Conclusion. Patients with demyelinating NPSLE should be tested for IgG antibodies to AQP-4, MOG, and DWEYS. IgG anti-AQP-4 can be considered diagnostic for NMOSD, whereas none of these antibodies appear to be diagnostic for demyelinating NPSLE. Moreover, IgG anti-dsDNA are present in patients with NMOSD but are not cross-reactive with IgG anti-DWEYS, indicating that the antigenic stimulus and mechanisms of tissue damage are potentially different between demyelinating NPSLE and NMOSD.
Systemic lupus erythematosus (SLE) is a chronic inflammatory disease that is characterized by the presence of various autoantibodies. Neuropsychiatric manifestations of SLE (NPSLE) can be very severe, and the diagnosis remains challenging. There are a variety of clinical presentations that include neurologic and psychiatric symptoms. Both an increased frequency of mortality and a diminished quality of life, in comparison to SLE patients without neuropsychiatric manifestations, are features that are associated with NPSLE (1) . NPSLE is characterized by 19 neuropsychiatric syndromes, as defined by the American College of Rheumatology (ACR) 1999 nomenclature (2) . The frequency of these neuropsychiatric symptoms among SLE patients can be challenging to evaluate, and the frequencies vary widely in different patient studies, ranging from an incidence of neuropsychiatric symptoms in as few as 10% of SLE patients to as many as 90% (3) .
Attribution of symptoms to SLE is also complicated because specific biomarkers for NPSLE have yet to be identified. Many of the neuropsychiatric syndromes classified by the ACR are not unique to NPSLE and are also present in other autoimmune diseases. For example, demyelination syndrome in patients with NPSLE can result in clinical and imaging features similar to those found in multiple sclerosis (4) . Thus, the diagnosis of NPSLE is based on a combination of psychiatric and neurologic testing, magnetic resonance imaging (MRI), electroencephalography, nerve conduction studies, and cerebrospinal fluid analysis (5) . Postmortem brain studies in patients with NPSLE are rare, and the findings have suggested that there are a variety of different neuropathologic manifestations that can occur in patients with NPSLE, such as hemorrhage, cortical and subcortical atrophy, microinfarcts, and demyelination (6) .
Results of previous studies have suggested that certain antibodies, such as anti-ribosomal P protein or antiphospholipid antibodies, anti-Sm antibodies, complement components, and immune complexes, may be responsible for emergence of some of the focal or diffuse neuropsychiatric symptoms observed in NPSLE (7) (8) (9) (10) . To date, more than 100 different antibodies have been reported in patients with SLE or NPSLE (11), of which some might be directly associated with the disease. The identification of specific antibodies showing a potential association with discrete manifestations of NPSLE not only would facilitate early diagnosis and treatment, but also could result in increased understanding of disease pathogenesis and the development of therapeutic approaches with less severe immunosuppression.
Previously, investigators in our group demonstrated that antibodies against the amino acid sequence DWEYS, a consensus sequence in the extracellular domain of the GluN2A/GluN2B subunits of the neuronal N-methyl-D-aspartate (NMDA) receptor, can induce apoptosis of hippocampal neurons through excitotoxicity and have been linked to cognitive impairment in a mouse model (12) . IgG anti-DWEYS antibodies in patients with SLE display cross-reactivity with double-stranded DNA (dsDNA) (13) . Elevated titers of IgG anti-DWEYS are more frequently detected in patients with NPSLE than in healthy controls, and their presence is linked to spatial cognitive impairment (14, 15) . So far, there are no data addressing whether IgG anti-DWEYS have a role in demyelinating NPSLE, and it remains unknown whether these antibodies are also found in other neurologic diseases, such as neuromyelitis optica spectrum disorder (NMOSD), which is also a disease that mainly affects young women and which has characteristics that can overlap with those of demyelinating NPSLE (16) . In addition, some patients with NMOSD have been shown to develop SLE, or vice versa.
NMOSD is an autoimmune disease characterized by damage to the central nervous system (CNS), directed primarily to astrocytes, and the presence of serum antibodies that bind to the astrocytic water channel protein aquaporin 4 (AQP-4) (17) . Antibodies recognizing conformation-dependent epitopes of myelin oligodendrocyte glycoprotein (MOG) are found in a subgroup of patients with NMOSD who are negative for IgG anti-AQP-4 (18, 19) . NMOSD most commonly affects areas with high levels of AQP-4 expression, such as the brain, optic nerve, and spinal cord, often resulting in long-spanning, demyelinating spinal cord lesions and/or optic neuritis. Demyelination, particularly optic neuritis and myelitis, are also part of the spectrum of symptoms in NPSLE (2, 20, 21) . Although demyelination can be related to SLE activity, it can sometimes be difficult to distinguish NPSLE from NMOSD. Case reports suggest that some patients with NMOSD develop SLE, and vice versa (2, 16, 22, 23) , raising the possibility of an overlap between the 2 diseases and making it difficult to distinguish whether the demyelination is part of SLE or NMOSD, or possibly both diseases.
In addition, IgG anti-dsDNA and IgG antinuclear antibodies (ANAs), both of which are diagnostic hallmarks of SLE, can also be found in NMOSD (24) , although data on their frequency and role in NMOSD are 278 MADER ET AL sparse. Unlike in SLE, it is not known whether antidsDNA antibodies in NMOSD are cross-reactive with the NMDA receptor and whether they are also linked to the cognitive impairment often observed in patients with NMOSD (25) . The purpose of this study was to understand the antibody repertoire in NPSLE, especially in patients with demyelinating NPSLE and patients with NMOSD, and to investigate the frequency of all brain-reactive antibodies that have been associated with both diseases. We also wanted to establish the frequency of antibodies that have been shown to be associated with NPSLE, such as dsDNA antibodies and ANAs as well as IgG anti-DWEYS antibodies, in patients with NMOSD. The frequency and staining patterns of these brain-reactive antibodies were assessed in comparison to patients with SLE without neuropsychiatric manifestations and healthy controls.
PATIENTS AND METHODS
Patients. Patients with NMOSD were recruited from the Clinic of Neurology, Clinical Center of Serbia in Belgrade (n = 31) and the Northwell Health System in New York (n = 2). All patients with NMOSD met the revised diagnostic criteria for NMOSD (26) , and only patients without any clinical evidence of other autoimmune diseases were included in this study. Patients with SLE (n = 38) were recruited from the Feinstein Institute for Medical Research (FIMR) in New York or the Kitasato University School of Medicine in Japan (n = 1). All patients with SLE fulfilled the ACR revised classification criteria for SLE (27, 28) . Patients with active NPSLE or those with a history of NPSLE or other CNS events were excluded from the SLE group.
All patients with NPSLE were recruited in Japan, from the Kitasato University School of Medicine (n = 60) or at the Hokkaido University Graduate School of Medicine (n = 31), or were recruited from the Clinic of Neurology, Clinical Center of Serbia (n = 17). Patients with NPSLE fulfilled the ACR 1999 criteria for NPSLE (2) . Demyelination in NPSLE was identified on the basis of MRI findings. All patients with demyelinating NPSLE met the ACR 1999 criteria for demyelination (2) , and all had either transverse myelitis occurring at 2 different time points or transverse myelitis with white matter demyelination or optic neuropathy occurring at 2 different time points.
In addition, 106 healthy control subjects from the FIMR (n = 7), the Clinic of Neurology, Clinical Center of Serbia (n = 23), or the BioreclamationIVT bank (n = 76) were included in the analyses. The present study was approved by the Northwell Health Institutional Review Board. Blood samples were collected from patients with NMOSD, patients with SLE, and healthy controls according to protocols approved by the appropriate institutional review boards at each of the participating institutions.
All serum samples were stored at À20°C and thawed only once, to prevent freeze-thawing effects. Individuals provided informed consent through the appropriate institutional review boards. The investigators were blinded with regard to each patient's clinical information.
Cell-based assay for testing antibodies to AQP-4 and MOG. Antibodies to AQP-4 and MOG in the serum of all patients and controls were assessed using live cell-based assays, as previously described (18, 29) . All serum samples were analyzed at 209 and 409 screening dilutions, using human HEK 293T cells transfected with AQP-4 (M23 AQP-4 isoform) or MOG. Nontransfected cells were used as negative controls, to exclude nonspecific binding to HEK 293T cells. Antibody-positive samples were serially diluted, and the titers of each antibody were determined. High-titer IgG anti-MOG antibodies were defined as those with a titer of ≥80 times the mean value in healthy control serum.
For the detection of IgG anti-AQP-4 antibodies, cells transfected with the M23 isoform of AQP-4 were stained 72 hours following transfection. Briefly, cells were blocked with phosphate buffered saline (PBS)-10% fetal bovine serum (FBS), and then incubated with serum samples diluted in PBS-10% FBS for 1 hour at 4°C. Following washing steps with PBS-10% FBS, cells were incubated with Alexa 594-conjugated goat anti-human IgG (Life Technologies) diluted in PBS-10% FBS (4009 dilution) for 30 minutes at room temperature. Following washing with PBS-10% FBS, the cells were stained with DAPI and analyzed using a fluorescence microscope. Nontransfected cells were used as a negative control, and dead cells were excluded from the analysis. For the detection of IgG anti-MOG antibodies, we performed the same protocol as for IgG anti-AQP-4, but analyzed the samples 24 hours after transfection.
Determination of dsDNA antibodies in serum samples. Serum IgG anti-dsDNA antibodies in patients and healthy controls were determined as described previously, with some modifications (13, 14) . Briefly, half-well plates (Costar) were dry-coated with calf thymus DNA (400 lg/ml; Sigma). In order to produce dsDNA, the sonicated calf thymus DNA was filtered through a 0.45 lM nitrocellulose Millex HA syringe filter (Millipore). The plates were blocked with 3% FBS and subsequently incubated with serum in 509 and 1009 dilutions, followed by incubation with alkaline phosphatase (AP)-conjugated goat anti-human IgG (1,0009 dilution; Southern Biotechnology). The plates were then developed with AP substrate (Sigma), and the optical density at an absorbance of 405 nm was read using an automated plate reader (Victor3; PerkinElmer). Positive and negative controls were included in each plate. Cutoff values were calculated as the mean plus 4 times the SD of values in healthy control serum; the mean plus 2 SD was used to define antibody-positive serum.
Determination of DWEYS peptide-reactive antibodies in serum samples. Serum IgG anti-DWEYS antibodies in patients and healthy controls were determined by enzyme-linked immunosorbent assay (ELISA), as previously described (13, 14) . Briefly, half-well ELISA plates (Costar) were coated with streptavidin (2.5 lg/ml; Southern Biotechnology) in bicarbonate buffer (pH 8.6) overnight at 4°C. The plates were blocked with 2% bovine serum albumin (BSA) in PBS for 1 hour at room temperature, followed by incubation with biotinylated DWEYS peptide (5 lg/ml; Anaspec) in 0.2% BSA. The plates were then incubated with the serum samples (1009 dilution), followed by incubation with goat anti-human IgG conjugated to AP, diluted in 0.2% BSA (1,0009 dilution), for 1 hour. Subsequently, the plates were developed with AP substrate (Sigma), and the optical density at an absorbance of 405 nm was read using an automated plate reader (Victor 3; PerkinElmer). As a quality control, the same serum samples, either positive or negative for IgG anti-DWEYS, were assayed in each plate. All samples were assayed in triplicate. Cutoff values were calculated as the mean plus 4 times the SD of values in healthy control serum; the mean plus 2 SD was used to define antibody-positive serum.
Determination of ANAs in serum samples. ANAs in the serum from patients and healthy controls were determined using a QuantaLite ANA ELISA (Inova Diagnostics) following the manufacturer's instructions, with use of relevant positive and negative controls supplied by the kit. Briefly, the plates were blocked with 3% FBS-PBS and incubated with serum at 419 dilution, followed by incubation with AP-labeled IgG and subsequently with horseradish peroxidase substrate (included in the kit). The optical density, measured as the absorbance at 405 nm (expressed in arbitrary units, following the conversion specified by the manufacturer), was determined using an automated plate reader (Victor3; PerkinElmer). Cutoff values were calculated as the mean plus 4 times the SD of values in healthy control serum; the mean plus 2 SD was the cutoff used to define antibody-positive serum.
Determination of IgG anti-brain antibodies in serum samples. IgG anti-brain antibodies were analyzed in the same manner as previously described (30) . Briefly, 12-week-old, unmanipulated C57BL/6 mice (Jackson Laboratories) were anesthetized with isoflurane. The mouse brains were isolated after perfusion with 4% paraformaldehyde (PFA), using cardiac perfusion. Each extracted brain was postfixed overnight in 4% PFA and then incubated with 30% sucrose for 48 hours at 4°C. The brains were transferred to OCT embedding medium on dry ice and frozen at À80°C. Sagittal sections (12 lm) of mouse brain were cut on a cryostat and frozen at À80°C. IgG anti-brain antibodies were analyzed in the serum of patients using a 1009 dilution. Sections of the brain were washed 2 times with PBS and blocked with 3% BSA-4% goat serum diluted in PBS-0.1% Triton for 1 hour at room temperature. Subsequently, the sections were incubated with serum samples using a 1009 dilution for 1 hour at room temperature. Following 3 washing steps with PBS-Tween (10 minutes each), the slides were incubated with anti-human secondary antibodies, labeled with Alexa 488, for 1 hour at room temperature. Following washing, the slides were mounted with Dako mounting solution. As a quality control, we used the same positive and negative serum in each round of staining. In addition, a secondary antibody staining omitting the serum was included. All procedures in animals were approved by the FIMR Institutional Animal Care and Use Committee.
Statistical
RESULTS
Specificity of IgG anti-AQP-4 antibodies for NMOSD, and detection in only a few patients with demyelinating NPSLE. IgG anti-AQP-4 antibodies were analyzed in patients with SLE, patients with NPSLE, patients with NMOSD, and a large set of healthy controls, using a live cell-based assay (29) (results in patients with demyelinating NPSLE are shown in Figure 1 ). All patients and healthy controls analyzed in this study were matched for sex 
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MADER ET AL and age (details on the demographic characteristics of all subjects are available upon request from the corresponding author). IgG anti-AQP-4 were found in the serum of 27 (82%) of 33 patients with NMOSD. In contrast, IgG anti-AQP-4 were detected in only 3 (3%) of 108 patients with NPSLE (Table 1) . When we divided patients with NPSLE into those with and those without demyelination, IgG anti-AQP-4 were found in 3 (27%) of the 11 patients with demyelinating NPSLE (Table 1 and Figure 1 ), whereas none of the 97 patients with non-demyelinating NPSLE were positive for IgG anti-AQP-4. In addition, no IgG anti-AQP-4 antibodies were found in the 38 patients with SLE without neuropsychiatric manifestations or in the 106 healthy controls.
Serum anti-MOG antibodies detected in IgG anti-AQP-4-negative patients with NMOSD but rarely found in patients with NPSLE. A live cell-based assay (18) was used to detect antibodies recognizing conformationdependent epitopes of MOG (Table 2 ) (further details available upon request from the corresponding author).
High-titer IgG anti-MOG antibodies (titer range 80-20,480) were detected only in patients with NMOSD who were negative for IgG anti-AQP-4 (3 [50%] of 6 patients). IgG anti-MOG antibodies expressed at lower titers (titer levels <80) were found in 2 (18%) of 11 patients with demyelinating NPLSE and in 1 (1%) of 97 patients with non-demyelinating NPSLE. In addition, 5 (5%) of 106 healthy controls exhibited low titers of IgG anti-MOG antibodies (median titer level 20).
Specificity of anti-NMDAR (GluN2A/GluN2B) antibodies for SLE and NPSLE, with none detected in patients with NMOSD or healthy controls. We investigated the presence of IgG anti-DWEYS antibodies by ELISA in the serum of patients and healthy controls (Figures 2A and B ). There were no significant differences in the expression of IgG anti-DWEYS between healthy controls and patients with NMOSD. However, both in patients with SLE and in patients with NPSLE, significantly higher titers of IgG anti-DWEYS were observed (Figure 2A ). There was no significant difference in the titers of IgG anti-DWEYS antibodies Table 1 for other definitions. † By chi-square test.
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between patients with demyelinating NPSLE and patients with non-demyelinating NPSLE ( Figure 2B ). IgG anti-DWEYS antibodies were present in 59 (55%) of 108 patients with NPSLE and 11 (29%) of 38 patients with SLE (Table 3 ). In contrast, only 4 (4%) of 106 healthy controls and 4 (12%) of 33 patients with NMOSD had IgG anti-DWEYS reactivity. When we divided patients with NPSLE according to their demyelination status, 56 (58%) of 97 patients with non-demyelinating NPSLE exhibited IgG DWEYS antibodies, compared to 3 (27%) of 11 patients with demyelinating NPSLE, suggesting that these antibodies are not associated with demyelinating symptoms in NPSLE.
Differences in frequencies and staining patterns of IgG anti-brain antibodies in patients with SLE and patients with NPSLE compared to patients with NMOSD. Serum samples from patients and healthy controls were analyzed for IgG anti-brain antibodies in experiments using Figure 2 . Expression of antibodies to GluN2A/GluN2B (IgG anti-DWEYS) and IgG double-stranded DNA (anti-dsDNA) in the serum of patients with neuropsychiatric systemic lupus erythematosus (NPSLE), patients with SLE without neuropsychiatric manifestations, patients with neuromyelitis optica spectrum disorder (NMOSD), and healthy controls (HC) (A and C). Patients with NPSLE were also analyzed for serum IgG anti-DWEYS and anti-dsDNA antibodies according to their demyelination status (those without and those with demyelination) (B and D). Data in all patient groups and healthy controls are presented as the absorbance at an optical density of 405 nm. Symbols represent individual subjects; horizontal lines with bars indicate the mean AE SEM. Groups were compared by Mann-Whitney U test or Kruskal-Wallis test with Dunn's correction for multiple comparisons where appropriate. ** = P = 0.001 to 0.01; *** = P < 0.001. NS = not significant.
PFA-fixed rodent brain sections, which allowed us to observe whether there was a difference in the frequency (Table 3) Staining of the serum from patients with SLE as well as patients with NPSLE revealed a neuronal staining pattern (Figure 3 ). In contrast, IgG anti-brain antibodies in the serum of patients with NMOSD mostly showed a pattern of vasculature staining, sometimes accompanied by neuronal staining. Only 1 NPSLE serum sample, which harbored IgG anti-AQP-4 antibodies, showed staining of the vasculature. Two NPSLE serum samples, which were positive for low titers of IgG anti-AQP-4, did not show vasculature staining, but did exhibit neuronal staining.
Elevated levels of IgG anti-dsDNA in patients with SLE, patients with NPSLE, and patients with NMOSD compared to healthy controls. We next assessed the frequency of IgG anti-dsDNA antibodies in all patients and healthy controls (Table 3) . We used an ELISA that is designed to detect IgG anti-dsDNA, and not singlestranded DNA (ssDNA) antibodies, since ssDNA antibodies are removed by binding to a nitrocellulose filter. IgG anti-dsDNA were present in 20 (53%) of 38 patients with SLE and 83 (77%) of 108 patients with NPSLE, compared to 11 (33%) of 33 patients with NMOSD and 6 (6%) of 106 healthy controls. When stratified by demyelination status, 6 (55%) of 11 patients with demyelinating NPSLE and 77 (79%) of 97 patients with non-demyelinating NPSLE exhibited elevated titers of IgG anti-dsDNA. Table 1 for other definitions.
† P values for a significant trend between groups were determined using the chi-square test. ‡ Data were available from 96 patients. § Data were available from 104 control subjects. Patients with NMOSD had significantly higher levels of IgG anti-dsDNA compared to healthy controls ( Figure 2C) . However, the levels were significantly lower in patients with NMOSD than in patients with NPSLE. Since most patients with NMOSD are negative for IgG anti-DWEYS, dsDNA antibodies in patients with NMOSD are not cross-reactive with GluN2A/GluN2B, unlike that observed in patients with SLE and patients with NPSLE.
Patients with non-demyelinating NPSLE had IgG anti-dsDNA titers that were comparable to those in patients with demyelinating NPSLE (Figure 2D ). There was no significant difference in IgG anti-dsDNA reactivity between patients with demyelinating NPSLE and patients with NMOSD ( Figures 2C and D) .
Elevated levels of IgG ANAs in patients with SLE, patients with NPSLE, and patients with NMOSD compared to healthy controls. IgG ANAs were analyzed using a commercially available ANA ELISA plate. 
DISCUSSION
In this study, we analyzed the frequency of brainreactive antibodies in a large number of patients with NPSLE as compared to patients with SLE without neuropsychiatric manifestations. Our results showed no difference in the frequency of serum IgG anti-brain antibodies or in the neuronal staining pattern of these antibodies between patients with SLE and patients with NPSLE. This confirms the observations made in previous studies in animal models, showing that circulating autoantibodies directed against brain components are not sufficient to cause neuropathologic symptoms, and that a second insult is required to breach the blood-brain barrier and allow IgG anti-brain antibodies to access the CNS and thereby initiate disease pathogenesis. The route of entry of antibodies may contribute to differences in the clinical presentation of patients. In our study, we observed that the majority of patients with SLE and patients with NPSLE (~80% in each group) exhibited a neuronal staining pattern upon incubation of their serum with mouse brain tissue. Thus, serum antibodies both from patients with SLE and from patients with NPSLE appeared to be binding to neuronal antigens expressed particularly in the hippocampal and cortical areas of the rodent brain tissue. This region-specific binding could contribute to cognitive impairment, which is one of the most common symptoms in NPSLE (31) .
Identification of specific target antigens, such as the NMDA receptor, which is highly expressed within these areas, and associations with clinical symptoms are of central importance in future studies. Investigators in our group have previously recognized that anti-dsDNA antibodies, a hallmark finding in SLE, that cross-react with the GluN2A/GluN2B subunits of the neuronal NMDA receptor can cause neuronal damage upon breach of the blood-brain barrier, as assessed in a mouse model (13) . Presence of these antibodies is correlated with impairment of spatial cognition in rodents and humans (14, 32) and psychiatric manifestations in patients with NPSLE (33) . The frequency of GluN2A/GluN2B antibodies (IgG anti-DWEYS) was elevated both in patients with SLE and in patients with NPSLE compared to healthy controls, as has been previously shown (33) . Our results confirm these findings, showing a higher frequency of IgG anti-DWEYS in patients with NPSLE compared to patients with SLE. It remains questionable whether antidsDNA-anti-GluN2A/GluN2B cross-reactive antibodies are able to breach the blood-brain barrier by themselves. It has been suggested that they can bind to and activate endothelial cells to cause blood-brain barrier impairment alternately (34); however, they might require a secondary insult to breach the blood-brain barrier, such as activation of cytokines or chemokines, complement activation, or anti-endothelial antibodies (35) .
The frequency of IgG anti-dsDNA and IgG anti-DWEYS antibodies has not been tested in patients with demyelinating NPSLE, nor have they been tested in patients with NMOSD, which is another demyelinating disorder in young women that has been reported to overlap with SLE or share neurologic features with NPSLE. Since autoantibodies directed against the NMDA receptor possess pathogenic potential, it is important to know whether IgG anti-dsDNA antibodies in another CNS autoimmune disease cross-react with the NMDA receptor, or whether this specificity is specific to SLE.
We therefore investigated the frequency of IgG anti-dsDNA and IgG anti-DWEYS in the serum of patients with NMOSD, an inflammatory and demyelinating disease in which patients have recently been reported to harbor IgG anti-dsDNA antibodies (36) . The significance and pathogenicity of dsDNA antibodies in the course of NMOSD remains unknown. NMOSD is a disease of great interest for researchers, due to the discovery in 2005 of highly specific IgG anti-AQP-4 antibodies in the serum of patients (17) , which resulted in the classification of NMOSD as its own disease rather than being defined as a severe variant of multiple sclerosis (37) . IgG anti-AQP-4 are predictive of NMOSD (26) . Antibodies recognizing conformation-dependent epitopes of MOG (a protein expressed on the outer surface of the myelin sheath), which are found in a subgroup of IgG anti-AQP-4-negative patients with NMOSD (18, 38) , may also contribute to demyelination. The processes of demyelination, particularly myelitis and optic neuritis, are also observed in some patients with NPSLE and are one of the least understood symptoms in NPSLE.
Recently reported findings indicate that patients with NMOSD develop other autoimmune diseases at a high frequency (36) . An increasing number of case studies have described patients with SLE who develop NMOSD, or vice versa (16, 23) . Precise data on the frequency of NMOSD as a comorbidity of SLE is still mainly based on small studies and case reports, and needs further investigation (16) . Due to similar patterns of demyelination in some of the patients with NPSLE and patients with NMOSD, it can be difficult to distinguish whether the demyelination, particularly myelitis and/or optic neuritis, is part of the activity of SLE or part of the activity of NMOSD, or both (39) . NMOSD shares many typical features with NPSLE, such as a strikingly high preponderance in women and a beneficial response to immunosuppressive therapeutic approaches. In addition, serum IgG anti-dsDNA and IgG ANAs can be found in both patient groups.
In our study, we analyzed brain-reactive antibodies, including antibodies to DWEYS, MOG, and AQP-4. In addition, we analyzed dsDNA antibodies in a large cohort of patients with NPSLE, patients with SLE, and patients with NMOSD without any other autoimmune diseases. A large set of healthy controls was also included. Our results confirm that IgG anti-AQP-4 are present in the vast majority of patients with NMOSD, and we also show that these antibodies can also be found in a small number of patients with demyelinating NPSLE. The presence of IgG anti-AQP-4 in 3 of 11 patients with demyelinating NPSLE suggests that NPSLE patients with demyelination should be routinely tested for IgG anti-AQP-4. In that case, the diagnostic criteria for comorbid NMOSD would be met. In contrast, we did not find IgG anti-AQP-4 antibodies in patients with non-demyelinating NPSLE. Since IgG anti-AQP-4-negative patients with demyelinating NPSLE showed serum positivity for brainreactive antibodies, it is likely that additional antibodies play a role in the disease pathogenesis. Although~80% of patients with SLE or NPSLE had antibodies reactive to mouse brain tissue, with a neuronal staining pattern, particularly of the cortex and hippocampus, serum from only 61% of patients with NMOSD showed staining on rodent brain tissue. This finding may reflect the fact that PFA fixation can alter the conformational epitope dependency of IgG anti-AQP-4 antibodies. In addition, some studies have shown that IgG anti-AQP-4 antibodies preferentially bind to human brain tissue, rather than rodent brain. Another explanation could be that IgG anti-AQP-4 antibodies have to reach a certain titer to produce clear staining on rodent brain tissue.
Our finding that IgG anti-DWEYS were present in the serum of 58% of patients with non-demyelinating NPSLE and in 27% of patients with demyelinating NPSLE suggests that other antibodies or non-antibody-mediated mechanisms may be associated with demyelination. Despite the presence of dsDNA antibodies in 33% of patients with NMOSD, IgG anti-DWEYS were found in only 12% of these patients. IgG anti-dsDNA antibodies in NMOSD are not cross-reactive with DWEYS, indicating that there is a different trigger for their production, and potentially different mechanisms of tissue damage in this disease. It remains to be investigated whether IgG anti-dsDNA antibodies in patients with NMOSD cross-react with an antigen other than the NMDA receptor subunits GluN2A and GluN2B. Moreover, since predictive biomarkers are currently lacking, it would be important to investigate whether IgG anti-DWEYS positivity might be predictive of the development of NPSLE in patients with NMOSD.
